Anteris Technologies Global Corp. (ASX:AVR)
5.86
+0.20 (3.53%)
Aug 18, 2025, 3:58 PM AEST
ASX:AVR Revenue
Anteris Technologies Global had revenue of $618.00K USD in the quarter ending June 30, 2025, a decrease of -2.22%. This brings the company's revenue in the last twelve months to $2.48M, down -2.45% year-over-year. In the year 2024, Anteris Technologies Global had annual revenue of $2.70M, down -1.17%.
Revenue (ttm)
$2.48M
Revenue Growth
-2.45%
P/S Ratio
54.93
Revenue / Employee
$18.23K
Employees
136
Market Cap
207.72M AUD
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.70M | -32.00K | -1.17% |
Dec 31, 2023 | 2.74M | -384.72K | -12.33% |
Dec 31, 2022 | 3.12M | -2.55M | -44.93% |
Dec 31, 2021 | 5.66M | 203.73K | 3.73% |
Dec 31, 2020 | 5.46M | -6.54M | -54.48% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CSL Limited | 24.61B |
Pro Medicus | 212.98M |
Cochlear | 2.34B |
Sonic Healthcare | 9.33B |
Ramsay Health Care | 17.12B |
Telix Pharmaceuticals | 783.21M |
Ansell | 3.00B |
Mesoblast | 9.16M |
Anteris Technologies Global News
- 6 days ago - Anteris Technologies reports Q2 results - Seeking Alpha
- 5 months ago - Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV - GlobeNewsWire
- 5 months ago - Anteris Reports One-Year Patient Outcomes for DurAVR® THV - GlobeNewsWire
- 5 months ago - Anteris Technologies Global Corp. reports FY results - Seeking Alpha
- 5 months ago - Anteris Reports 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - Medtronic Q3 Earnings: Cardiovascular And Neuroscience Drive Growth, Surgical Revenue Dips, Reaffirms Annual Forecast - Benzinga
- 7 months ago - Anteris Technologies Positioned To Capture 4%-5% Of US Transcatheter Valve Replacement Market By 2030: Analyst - Benzinga
- 8 months ago - Anteris Technologies Global Corp. Announces Closing of $88.8 Million U.S. Initial Public Offering - Business Wire